09:57 AM EST - Valeant Pharmaceuticals International, Inc. : and GlaxoSmithKline announced today that the U.S. Food and Drug Administration (FDA) has approved Potiga(TM) (ezogabine) Tablets, a potassium channel opener, as adjunctive treatment of partial-onset seizures in patients aged 18 years and older. Valeant Pharmaceuticals International, Inc.
shares T.VRX are trading up $0.44 at $52.20.
